A review published in
Genes & Diseases highlights how changes to sugar molecules on cancer cells could help tumours grow, spread, resist treatment, and evade immune attack. Researchers at Shandong Provincial Hospital, affiliated to Shandong First Medical University, examine
abnormal sialylation and its potential to guide cancer diagnosis and the development of targeted therapies.
Sialylation is the process of adding sialic acids to sugar chains attached to proteins and fats. These molecules help regulate normal cell communication and biological functions. In cancer, however, their abundance and arrangement can change, altering how tumour cells interact with tissues and the immune system.
The review brings together evidence across
solid tumours and blood cancers, including gastric, colorectal, breast, lung, and pancreatic cancers, as well as leukaemia and multiple myeloma. It examines two enzyme groups that control this process:
sialyltransferases, which add sialic acids, and
neuraminidases, which remove them. Disruption of this balance can influence tumour behaviour.
One important mechanism involves
immune evasion. Sialic acids displayed on tumour cells can engage receptors called
Siglecs on immune cells, sending signals that suppress anticancer responses. This interaction creates opportunities for therapies designed to interrupt those signals or remove sialic acids from tumour surfaces.
The article also explores links between abnormal sialylation and
drug resistance. Studies reviewed suggest that changes in the enzyme
ST6Gal1 can affect responses to treatments such as trastuzumab in gastric cancer. Other findings connect altered sialylation with resistance in colorectal cancer and leukaemia, supporting further investigation into combinations with existing treatments.
Potential approaches include sialyltransferase inhibitors, antibodies targeting Siglecs, and
antibody–sialidase conjugates that direct sugar-removing enzymes towards cancer cells. Engineered immune cells and proteins that recruit T cells while modifying tumour surface sugars also show promise in experimental models.
Beyond treatment, sialylation patterns could provide
biomarkers for detecting cancer, assessing disease progression, or predicting treatment response. The review describes analytical technologies, including mass spectrometry and molecular imaging approaches, that could help researchers identify these patterns more precisely.
Important challenges remain. Sialylation also supports healthy tissues, and broad inhibition has caused liver and kidney dysfunction in animal studies. Its effects differ between cancers, with some findings suggesting protective roles. Developing
selective treatments and validating biomarkers are therefore essential.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 |Impact Factor:14.6
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available
online in
ScienceDirect (
https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to
Genes & Diseases may be made using
Editorial Manager (
https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (
https://x.com/GenesNDiseases)
# # # # # #
Reference
Ran Kong, Cong Wang, Yu Zhang, Guangcai Zhong, Jiarui Liu, Xiangxiang Zhou, Aberrant sialylation in cancer: From molecular mechanisms to potential therapeutics, Genes & Diseases, Volume 13, Issue 6, 2026, 102080,
https://doi.org/10.1016/j.gendis.2026.102080
Funding
National Natural Science Foundation of China
82570247
National Natural Science Foundation of China
82170189
Shandong Provincial Natural Science Foundation
ZR2021YQ51
Shandong Provincial Natural Science Foundation
ZR2022QH204
Taishan Scholars Program of Shandong Province, China
tstp20250756